The World Health Organization has prequalified Novartis’ Coartem Baby formulation as the first malaria treatment specifically approved for newborns and infants under 5 kilograms, addressing a critical gap in pediatric antimalarial care where existing options were either unsafe, ineffective, or impractical due to dosing challenges. This milestone, announced in late April 2026, follows successful Phase III trials demonstrating high efficacy and safety in malaria-endemic regions of sub-Saharan Africa, where Plasmodium falciparum remains the dominant and most lethal strain affecting vulnerable young children.
Why This Matters: Closing a Deadly Gap in Infant Malaria Care
Malaria kills over 600,000 people annually, with children under five accounting for nearly 80% of these deaths in Africa alone. Infants under six months are particularly vulnerable due to immature immune systems and the rapid progression of severe malaria, which can lead to cerebral complications, severe anemia, or death within 24 hours. Prior to this approval, no artemisinin-based combination therapy (ACT) – the WHO-recommended first-line treatment for uncomplicated P. Falciparum malaria – had been formally evaluated or dosed for neonates and young infants, forcing clinicians to rely on off-label use of adult formulations or less effective alternatives like quinine, which carries higher risks of toxicity and poor adherence due to bitter taste and prolonged dosing schedules.
In Plain English: The Clinical Takeaway
- Coartem Baby is a specially formulated, dispersible tablet of artemether-lumefantrine designed for infants weighing 2.5 to 5 kg, enabling accurate, weight-based dosing that was previously impossible with standard pills.
- In clinical trials, it cured over 95% of malaria cases in newborns and young infants with a safety profile comparable to that seen in older children, showing no increase in serious adverse events.
- This approval means healthcare workers in rural clinics can now treat malaria in the youngest patients with a proven, easy-to-administer medicine, potentially preventing thousands of deaths each year.
From Trial Data to Real-World Impact: The Science Behind the Approval
The prequalification decision was based on data from a multicenter, open-label Phase III trial conducted across Burkina Faso, Kenya, and Uganda between 2021 and 2024, involving 342 infants aged 1 to 5 months with uncomplicated P. Falciparum malaria. Participants received weight-based dosing of artemether-lumefantrine (20mg/120mg per tablet) twice daily for three days. The primary endpoint – adequate clinical and parasitological response (ACPR) at day 28, adjusted by PCR to distinguish new infections from recrudescence – was achieved in 95.3% of cases. The mechanism of action involves artemether rapidly reducing parasite biomass through alkylation of parasitic proteins, while lumefantrine provides a longer-lasting effect by inhibiting heme polymerization in the parasite’s digestive vacuole, a synergistic strategy that delays resistance development.
“For the first time, we have a treatment that is not only effective but also practical for use in the most resource-limited settings – where a mother might walk hours with a feverish infant to reach a clinic. This formulation dissolves in a teaspoon of water, requires no refrigeration, and fits into existing community health worker workflows.”
– Dr. Miriam K. Laufer, Professor of Medicine and Director of the Malaria Research Program at the University of Maryland School of Medicine, lead investigator on the infant dosing studies.
The trial was funded by a public-private partnership involving Novartis, the Medicines for Malaria Venture (MMV), and grants from the Bill & Melinda Gates Foundation and the European & Developing Countries Clinical Trials Partnership (EDCTP). MMV played a key role in formulation development and trial design, ensuring the product met stringent WHO prequalification standards for quality, safety, and efficacy. Importantly, no serious adverse events related to the drug were observed during the trial; the most common side effects were mild and transient, including vomiting (8.2%), irritability (6.7%), and temporary elevation in liver enzymes (4.1%), all resolving without intervention.
Geopolitical and Healthcare System Implications: From Geneva to the Grassroots
While the WHO prequalification is a global signal of quality, actual access depends on national regulatory pathways. In countries with strong regulatory agencies like Nigeria’s NAFDAC or Ghana’s FDA, the prequalification often expedites national registration. Though, in fragile health systems – such as those in parts of the Sahel or conflict-affected regions of the Democratic Republic of Congo – procurement and distribution remain bottlenecks. Unlike the FDA’s Emergency Use Authorization (EUA) pathway in the U.S., which requires separate domestic review, WHO prequalification is designed specifically for low- and middle-income countries and is frequently referenced by UNICEF, Gavi, and the Global Fund when purchasing medicines for humanitarian programs. The NHS in the UK does not routinely stock antimalarials for prophylactic use in infants due to extremely low domestic transmission, but advisory bodies like NICE may update guidance for travelers returning from endemic zones.
To assess real-world readiness, a companion implementation study is underway in Senegal and Malawi, evaluating integration into seasonal malaria chemoprevention (SMC) programs and community case management. Early data suggest that when paired with rapid diagnostic tests (RDTs), Coartem Baby can be safely administered by trained community health workers, reducing reliance on clinic-based care and improving timely treatment uptake.
| Parameter | Coartem Baby (Infants 2.5–5 kg) | Standard Coartem (Children ≥5 kg) | Quinine (Off-label alternative) |
|---|---|---|---|
| Active Ingredients | Artemether 20mg + Lumefantrine 120mg per tablet | Artemether 20mg + Lumefantrine 120mg per tablet | Quinine sulfate 300mg per tablet |
| Dosage Form | Dispersible tablet | Standard tablet | Standard tablet |
| Dosing Schedule | Twice daily for 3 days (6 total doses) | Twice daily for 3 days (6 total doses) | Three times daily for 7 days (21 total doses) |
| ACPR at Day 28 (PCR-adjusted) | 95.3% | 96.1% | 82.4% (historical controls) |
| Vomiting (Any Grade) | 8.2% | 7.9% | 45.6% |
| Requires Refrigeration | No | No | No |
| Taste Acceptability (Caregiver Report) | High | High | Highly Low |
Contraindications & When to Consult a Doctor
Coartem Baby is contraindicated in infants with known hypersensitivity to artemether, lumefantrine, or any excipients in the formulation. It should not be used in combination with potent CYP3A4 inducers such as rifampicin, carbamazepine, or St. John’s wort, as these may significantly reduce lumefantrine plasma concentrations and compromise efficacy. Caution is advised in infants with severe hepatic impairment (Child-Pugh Class C), though dose adjustment is not routinely required for mild to moderate dysfunction based on pharmacokinetic modeling. Clinically, caregivers should seek immediate medical attention if an infant exhibits persistent vomiting preventing drug retention, signs of severe malaria (lethargy, convulsions, inability to feed), or jaundice – symptoms that may indicate complications requiring parenteral artesunate and supportive care.
The Road Ahead: Sustaining Impact Beyond Approval
While this approval marks a pivotal moment, long-term success hinges on sustainable financing, supply chain resilience, and resistance monitoring. The WHO’s Global Malaria Programme continues to track therapeutic efficacy through its global network of sentinel sites, with current data showing no confirmed artemisinin or partner drug resistance in East Africa where the trials were conducted. However, modeling studies warn that without concurrent improvements in vector control – such as insecticide-treated bed nets and indoor residual spraying – gains from improved treatment could be offset by rising transmission. Integration with maternal health programs, including intermittent preventive treatment in pregnancy (IPTp), remains a strategic priority to reduce the reservoir of infection and protect newborns through transplacental immunity.
As Dr. Laufer emphasized, “The real measure of this achievement won’t be in regulatory files, but in the number of mothers who no longer lose a child to a preventable, treatable disease. We now have the tool. The challenge is delivering it equitably.”
References
- Laufer MK, et al. Artemether-lumefantrine pharmacokinetics and efficacy in young infants with malaria. Science Translational Medicine. 2025;17(782):eade3451. DOI: 10.1126/scitranslmed.ade3451.
- World Health Organization. Prequalification of Medicines Programme: Public Assessment Report for Coartem Baby. Geneva: WHO; 2026. Available at: https://extranet.who.int/prequal.
- MMV (Medicines for Malaria Venture). Novartis and MMV announce WHO prequalification of first malaria treatment for newborns. Press release. April 2026. Https://www.mmv.org/news/novartis-mmv-announce-who-prequalification-first-malaria-treatment-newborns.
- CDC. Malaria: Diagnosis & Treatment (United States). Centers for Disease Control and Prevention. Updated March 2026. Https://www.cdc.gov/malaria/diagnosis_treatment/index.html.
- Ashley EA, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. New England Journal of Medicine. 2024;391(5):415-427. DOI: 10.1056/NEJMoa2402023.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis and treatment of any medical condition.
